Related Experiment Videos
Novel therapies in multiple myeloma
1Multiple Myeloma Program, Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA. s-singhal@northwestern.edu
International Journal of Hematology
|May 7, 2003
Summary
Thalidomide revolutionized myeloma treatment, inspiring research into new non-chemotherapeutic agents. These novel drugs show promise for relapsed or refractory myeloma and may become frontline therapies.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The late 1990s discovery of thalidomide's efficacy in multiple myeloma marked a paradigm shift in treatment.
- This breakthrough stimulated extensive clinical research into novel, non-chemotherapeutic agents for myeloma therapy.
Purpose of the Study:
- To review the impact of thalidomide and other novel agents in multiple myeloma treatment.
- To highlight promising new therapies and their potential role in current and future myeloma management.
Main Methods:
- Review of clinical investigations and preliminary data on novel agents for multiple myeloma.
- Analysis of thalidomide's therapeutic benefit across different disease stages.
- Examination of in vitro and in vivo data on drug synergy.
Main Results:
- Thalidomide offers significant therapeutic benefit at all stages of multiple myeloma.
- Novel agents like CC-5013, bortezomib, arsenic trioxide, ENMD 0995, and 2-methoxyestradiol show activity in relapsed/refractory disease.
- Some agents demonstrate efficacy even after failure of other novel treatments, with evidence of synergy between agents.
Conclusions:
- Thalidomide is an essential therapeutic option for all multiple myeloma patients.
- Novel agents are increasingly important for refractory/relapsed myeloma and are likely to be integrated into frontline therapy, potentially in combination with chemotherapy.